- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04609800
Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France. (CAROLINE)
December 17, 2020 updated by: Ipsen
CAROLINE: An Observational, Prospective, Multicenter Study, on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.
Study Overview
Status
Withdrawn
Conditions
Study Type
Observational
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Data of 195 participants suffering from advanced or metastatic RCC and treated with cabozantinib will be collected.
During the study, two questionnaires (FKSI 19 and BPI-SF) will be filled in by patients.
Description
Inclusion Criteria:
- Male or female ≥ 18 age at the time of cabozantinib initiation
- Pathologically confirmed diagnosis of Renal Cell Carcinoma (Clear Cell or non-Clear Cell) cancer considered as advanced or metastatic at the time of cabozantinib initiation
- Intention to be treated with cabozantinib tablets according to the current local Summary of Product Characteristics (SmPC) (France)
- Initiating cabozantinib as a second line of treatment (Baseline visit must be performed before cabozantinib first intake)
Exclusion Criteria:
- He/she is already included in an interventional trial with an investigational product at the same time.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS) rate at 1 year after cabozantinib initiation
Time Frame: up to 12 months
|
OS is the time between treatment initiation and the date of death from any cause.
For participants who are alive, their survival time will be censored at the last date that they were known to be alive if before 1 year.
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR) at 1 year
Time Frame: Day 15, 1 month, 3, 6 and 12 months
|
ORR is defined as the proportion of participants who achieve partial or complete response from the start of the study treatment.
The ORR will be assessed by tumour response evaluation according to investigator assessment.
Tumour response will be evaluated per routine clinical practice by the physician.
|
Day 15, 1 month, 3, 6 and 12 months
|
Best Overall Response (BOR) at 1 year
Time Frame: Day 15, 1 month, 3, 6 and 12 months
|
BOR is the best response recorded from the start of the study treatment until the disease progression/recurrence.
The BOR will be assessed by tumour response evaluation according to investigator assessment.
Tumour response will be evaluated per routine clinical practice by the physician.
|
Day 15, 1 month, 3, 6 and 12 months
|
Progression Free Survival (PFS) at 1 year
Time Frame: Day 15, 1 month, 3, 6 and 12 months
|
PFS is defined as the time elapsed from the date of first treatment intake to the date of documented progression reported by the investigator or death due to any cause, whichever occurs first.
Disease progression will be assessed by tumour response evaluation according to investigator assessment.
Tumour response will be evaluated per routine clinical practice as Progressive / not progressive disease by the physician.
|
Day 15, 1 month, 3, 6 and 12 months
|
Previous systemic neoadjuvant and adjuvant therapies for RCC prior cabozantinib initiation in terms of nature of the therapy, duration, and reason for discontinuation.
Time Frame: Baseline
|
Baseline
|
|
First-line therapy for RCC prior cabozantinib initiation in terms of nature of the therapy, duration, and reason for discontinuation.
Time Frame: Baseline
|
Baseline
|
|
Pattern of use of cabozantinib
Time Frame: Baseline, day 15, 1 month, 3, 6 and 12 months
|
Dose modification, reason of modification and treatment duration of cabozantinib will be described from cabozantinib initiation until participants' end of study treatment or study withdrawal.
|
Baseline, day 15, 1 month, 3, 6 and 12 months
|
Quality of life (QoL) change according to Functional Assessment of Cancer Therapy (FKSI-19) questionnaire
Time Frame: Baseline, day 15, 1 month, 3, 6 and 12 months
|
QoL change from baseline.
The score will be evaluated with FKSI 19 questionnaires at the planned visits and at treatment discontinuation.
The FKSI-19 is a disease-specific instrument that measures disease and treatment-related symptoms in 4 domains by using a 5-point scale (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much).
Higher scores represent better health.
A negative change from Baseline represents a worsening of condition.
|
Baseline, day 15, 1 month, 3, 6 and 12 months
|
Pain assessment
Time Frame: Baseline, day 15, 1 month, 3, 6 and 12 months
|
To assess pain according to the Brief Pain Inventory-Short Form (BPI-SF) questionnaire and analgesic consumption/duration and the time for improvement of symptomatology.
BPI-SF has a scale of 0 to 10 with 0 indicating "No pain" and 10 indicating "Pain as bad as you can imagine".
|
Baseline, day 15, 1 month, 3, 6 and 12 months
|
Subsequent systemic treatment for RCC after cabozantinib discontinuation in terms of the description of the nature of the therapy, starting date.
Time Frame: End of Study visit (12 months if the patient didn't discontinue earlier)
|
End of Study visit (12 months if the patient didn't discontinue earlier)
|
|
Safety of cabozantinib in the real-world setting
Time Frame: Day 15, 1 month, 3, 6 and 12 months
|
Incidence of Adverse Events (AEs),Serious Adverse Events (SAEs) assessed overall and by intensity and causality.
|
Day 15, 1 month, 3, 6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 6, 2020
Primary Completion (Anticipated)
May 10, 2023
Study Completion (Anticipated)
May 10, 2023
Study Registration Dates
First Submitted
October 7, 2020
First Submitted That Met QC Criteria
October 29, 2020
First Posted (Actual)
October 30, 2020
Study Record Updates
Last Update Posted (Actual)
December 21, 2020
Last Update Submitted That Met QC Criteria
December 17, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-FR-60000-070
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Australian and New Zealand Urogenital and Prostate...RecruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11.2 Translocation-Related Renal Cell CarcinomaAustralia
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRecruitingRenal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWithdrawnMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingChromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Fumarate Hydratase Deficient Renal Cell Carcinoma | Succinate Dehydrogenase Deficient Renal Cell Carcinoma | Collecting Duct Renal...United States
-
Australian and New Zealand Urogenital and Prostate...Bristol-Myers SquibbActive, not recruitingRenal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation CarcinomaAustralia
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingUnresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell CarcinomaUnited States, Canada